Compare Expeditors International of Wshngtn Inc (EXPD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Expeditors International of Wshngtn Inc trades at $195.87 (market cap $25.37B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 5.2× Travere Therapeutics Inc. Common Stock's market cap, and Expeditors International of Wshngtn Inc pays a 0.83% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 44 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EXPD | TVTX | |
|---|---|---|
Market Cap | $25.37B | $4.88B |
Volume | 1,236,812 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $196.38 | $67.52 |
52-Week Low | $117.35 | $26.79 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $24.90B | $5.01B |
Dividend Yield | 0.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $196.38, up 1.54% today, with a bullish technical signal from moving averages and strong profitability metrics including a 42.6% ROE. Recent quarters show consistent earnings beats, and cash flow improved to a positive $166 million in 2025. News highlights efficiency initiatives and AI's impact on freight markets, supporting positive momentum.
The stock's outlook is mixed; fundamentals are solid with revenue growth to $12.0B projected for 2026, but valuation is elevated at a P/E of 28.4, and analyst consensus is cautious with a $179.43 price target below current levels. Risks include reliance on freight demand cycles and competitive pressures in logistics.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
